Azacitidine Ropeginterferon trial NCT07646821
Phase 1b/2 trial NCT07646821 adds ropeginterferon alfa-2b to azacitidine in TP53-mutated MDS/AML; ChEMBL, ClinicalTrials.gov and DepMap data as of 2026-11-15.
Data as of November 15, 2026 · By the BioQ team

The azacitidine Ropeginterferon trial NCT07646821 is a PHASE1/PHASE2 study at M.D. Anderson Cancer Center, with a listed start of 2026-10-27. For azacitidine, ChEMBL holds 73 targets, and the strongest is DNMT1 at a best pChEMBL of 6.52. ClinicalTrials.gov matches 459 azacitidine studies. TP53 knockout is a dependency in only 4 of 1178 DepMap cell lines. All data are as of 2026-11-15.
What we asked: the azacitidine and ropeginterferon trial
The trial is titled "A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations". It adds ropeginterferon alfa-2b to azacitidine in patients whose myelodysplastic syndrome or acute myeloid leukemia carries a TP53 mutation. The sponsor is M.D. Anderson Cancer Center, the phase is PHASE1/PHASE2 and the registered start date is 2026-10-27.
We split this into four questions that BioQ can answer from public data:
- What does ChEMBL record as measured targets of azacitidine, and how potent are the exact measurements?
- How many other azacitidine trials are registered, and at which phases?
- How does the TP53 gene, the mutation context of this trial, behave in cancer cell-line dependency screens?
- Which drugs are already known for TP53?
The one query we ran was azacitidine. The TP53 blocks come from the gene-level layers that BioQ connects to the same answer.
What BioQ returned
The first block lists the strongest measured targets of azacitidine in ChEMBL (compound CHEMBL1489). Across the 73 targets, 14 have at least one exact measurement. The table shows the top 8 by best pChEMBL, which is the negative log10 of the molar potency.
| ChEMBL target | Gene | Best pChEMBL | Type | Exact measurements |
|---|---|---|---|---|
| CHEMBL1993 | DNMT1 | 6.52 | IC50 | 1 |
| CHEMBL2366181 | — | 6.47 | IC50 | 1 |
| CHEMBL386 | — | 6.39 | IC50 | 1 |
| CHEMBL612545 | — | 6.3 | IC50 | 28 |
| CHEMBL614515 | — | 6.2 | IC50 | 1 |
| CHEMBL397 | — | 5.97 | IC50 | 1 |
| CHEMBL3879801 | — | 5.8 | IC50 | 1 |
| CHEMBL612565 | — | 5.76 | IC50 | 1 |

The second block shows a page of 6 registered azacitidine trials. Across all 459 matched studies, 209 are phase 1, 262 are phase 2 and 54 are phase 3. The phase counts overlap because some studies are registered as combined phases.
| Trial | Phase | Status | Sponsor | Start | Enrollment |
|---|---|---|---|---|---|
| NCT04128020 | PHASE1 | WITHDRAWN | Sherif Farag | 2019-10 | — |
| NCT00454480 | PHASE2/PHASE3 | COMPLETED | The University of New South Wales | 2006-08 | 2000 |
| NCT02508870 | PHASE1 | COMPLETED | Hoffmann-La Roche | 2015-09 | 46 |
| NCT07754799 | PHASE2 | NOT_YET_RECRUITING | Institute of Hematology & Blood Diseases | 2026-09 | 320 |
| NCT00118287 | PHASE1/PHASE2 | COMPLETED | Fred Hutchinson Cancer Center | 2005-04 | 32 |
| NCT05788679 | PHASE2 | RECRUITING | Karolinska University Hospital | 2022-11 | 200 |
The third block covers TP53 in DepMap (release depmap_24q4, Chronos gene effect). Of 1178 cell lines, 4 count as dependent, which is 0.3 percent. The mean gene effect is 0.379 and TP53 is not flagged as common essential. The table shows the top 5 lineages returned, including myeloid.
| Lineage | Cell lines | Dependent | % dependent | Mean gene effect |
|---|---|---|---|---|
| Head and Neck | 77 | 1 | 1.3 | 0.133 |
| Breast | 53 | 1 | 1.9 | 0.176 |
| Pancreas | 47 | 0 | 0 | 0.193 |
| Myeloid | 42 | 1 | 2.4 | 0.194 |
| Esophagus/Stomach | 69 | 0 | 0 | 0.223 |
The drug layer lists 18 drugs known for TP53. Among them, Navtemadlin and Idasanutlin are at PHASE_3 with best exact pChEMBL values of 9.22 and 8.22, both IC50. Eprenetapopt is also listed at PHASE_3 as a p53 stabiliser, and 1 trial matches it by name in ClinicalTrials.gov.
The five queries drew on 5 distinct resources and took 0.55 engine seconds in total. Doing the same by hand would mean separate visits to ChEMBL, ClinicalTrials.gov, PubChem, DepMap and a drug-target layer, each with its own identifiers. The compound block resolves azacitidine to PubChem CID 9444 and to CHEMBL1489, which links the layers without manual ID mapping.
What it means and how to read it
The intervention. DNMT1 is the only row in the potency table with a gene symbol. Its best pChEMBL is 6.52 (IC50), from 1 exact measurement. A single measurement is a thin basis, so treat it as a recorded value and not as a settled potency. The row CHEMBL612545 has 28 exact measurements and a best pChEMBL of 6.3. It has no gene symbol in this table, so we do not interpret it as a protein target. The remaining rows have 1 exact measurement each.
The trial in context. With 459 registered azacitidine studies, the drug appears in a large number of trials. The 6 rows shown include a PHASE2 study that is not yet recruiting (NCT07754799, planned enrollment 320) and a recruiting PHASE2 study (NCT05788679, 200). These are a page of the result, not a ranking, and the new trial is not necessarily among them.
The TP53 context. The trial selects for TP53 mutation, which is a feature of the patients' disease and not a recorded target of azacitidine. In DepMap, TP53 knockout rarely reduces viability: 4 of 1178 lines are dependent, and in the myeloid lineage 1 of 42 lines is. A positive mean gene effect means that on average the knockout did not reduce viability in these screens. A CRISPR screen does not show whether a patient benefits from a combination.
Drugs already aimed at TP53. In the 6 rows shown of the 18 drugs known for TP53, the entries are MDM2 inhibitors or other p53-directed agents, apart from Aspirin. This helps place the trial among other TP53-focused approaches. Ropeginterferon alfa-2b is not in the rows shown.
How to reproduce it in BioQ
- Open BioQ and enter the compound name as the query.
- Run the query below and wait for the answer, which took 0.55 engine seconds in our run across 5 queries.
azacitidine
- Open the targets view and sort by best pChEMBL. Check the number of exact measurements for each row before you compare potencies.
- Open the clinical trials view for azacitidine and filter by phase or status. Look for NCT07646821 by its identifier.
- Query TP53 to see the DepMap lineage table and the drugs known for the gene. Each result names its source and release, so you can cite it.
Limits: what the data do not show
- BioQ's results here do not cover ropeginterferon alfa-2b. We make no statement about its potency, targets or other trials.
- The trial record gives a title, sponsor, phase and start date. It does not tell us outcomes, doses or response rates, and we state none.
- Potency values in ChEMBL come from assays that differ in design. A best pChEMBL from 1 measurement is not a comparison of efficacy between targets.
- DepMap measures knockout in cell lines. It does not model a TP53 point mutation, immune effects, or an interferon combination.
- The azacitidine trial page is a sample of 6 from 459 studies. Phase counts overlap and do not sum to the total.
- Nothing here is medical advice or a judgement on whether the combination will help patients.
Data and method
The numbers on this page were read from the BioQ engine on 2026-11-15 (5 queries, 0.6 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.
/chembl_potency, /clinicaltrials, /compound, /depmap, /drugs
Sources
- A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in MDS/AML With TP53 Mutations (2026) — https://clinicaltrials.gov/study/NCT07646821
Run the same query yourself: azacitidine
For research use only. This page summarises public data and is not medical advice.
BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.
Queries used
Frequently asked questions
What does NCT07646821 test?
It is a PHASE1/PHASE2 study from M.D. Anderson Cancer Center of ropeginterferon alfa-2b added to azacitidine in MDS/AML with TP53 mutations. The registered start date is 2026-10-27.
What is the strongest measured target of azacitidine in ChEMBL?
DNMT1 has the highest best pChEMBL among the rows with a gene symbol, at 6.52 (IC50) from 1 exact measurement. In total ChEMBL lists 73 targets, 14 of them with exact measurements.
How many azacitidine clinical trials are registered?
ClinicalTrials.gov matches 459 studies for azacitidine as of 2026-11-15. Of these, 209 are phase 1, 262 are phase 2 and 54 are phase 3.
Is TP53 a dependency in cancer cell lines?
Rarely. In DepMap depmap_24q4, TP53 knockout counts as a dependency in 4 of 1178 cell lines (0.3 percent), and the gene is not common essential. In the myeloid lineage, 1 of 42 lines is dependent.
Which drugs are known for TP53?
BioQ lists 18 drugs for TP53. Navtemadlin and Idasanutlin, both MDM2 inhibitors, are at PHASE_3 with best exact pChEMBL values of 9.22 and 8.22.
Sources
Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
More from the blog
MDM2 vs MDM4: dependency and drugs side by side
MDM2 vs MDM4 in DepMap 24q4 Chronos data and drug annotations: 384 of 1178 cell lines depend on MDM2, 142 on MDM4; 12 drugs listed for MDM2, 1 for MDM4.
Tiratricol FDA approval: targets and potency in BioQ
Tiratricol FDA approval (Emcitate): ChEMBL shows 68 targets, THRB and THRA top by pChEMBL, and 3 registered trials on ClinicalTrials.gov, as of 2026-11-17.
Carboplatin Non-Small Cell Lung Cancer trial: NCT07877584
NCT07877584 is a phase 3 NSCLC trial of PD-1 blockade with or without chemotherapy; BioQ adds carboplatin ChEMBL potency and ClinicalTrials.gov context.


